X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
XC001 (encoberminogene rezmadenovec) is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow in patients with refractory angina.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, it may decrease chest pain associated with refractory angina.
Lead Product(s): XC001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
XC001 (encoberminogene rezmadenovec) is a locally administered, single-dose gene therapy currently in development as a novel approach to treating patients with refractory angina who have no other medical and surgical options.
Lead Product(s): XC001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study.
Lead Product(s): XC001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
XyloCor also confirms that it plans to submit an additional Phase 2 clinical study to the U.S. Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21.
Lead Product(s): AdVEGFXC1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
The financing will enable XyloCor to expand its clinical development program for XC001, including the initiation of a new trial of XC001 as a potential adjunctive therapy to augment the effectiveness of coronary artery bypass graft surgery (CABG).
Lead Product(s): AdVEGFXC1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fountain Healthcare Partners
Deal Size: $41.9 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 22, 2021
Details:
XyloCor dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
Lead Product(s): XC001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
